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Abstract
Background: In this era of a constantly changing landscape of antiviral treatment options for chronic viral hepatitis
C (CHC), shared clinical decision-making addresses the need to engage patients in complex treatment decisions.
However, little is known about the decision attributes that CHC patients consider when making treatment
decisions. We identify key patient-centered decision attributes, and explore relationships among these attributes, to
help inform the development of a future CHC shared decision-making aid.
Methods: Semi-structured qualitative interviews with CHC patients at four Veterans Health Administration (VHA)
hospitals, in three comparison groups: contemplating CHC treatment at the time of data collection (Group 1),
recently declined CHC treatment (Group 2), or recently started CHC treatment (Group 3). Participant descriptions of
decision attributes were analyzed for the entire sample as well as by patient group and by gender.
Results: Twenty-nine Veteran patients participated (21 males, eight females): 12 were contemplating treatment,
nine had recently declined treatment, and eight had recently started treatment. Patients on average described
eight (range 5–13) decision attributes. The attributes most frequently reported overall were: physical side effects
(83 %); treatment efficacy (79 %), new treatment drugs in development (55 %); psychological side effects (55 %);
and condition of the liver (52 %), with some variation based on group and gender. Personal life circumstance
attributes (such as availability of family support and the burden of financial responsibilities) influencing treatment
decisions were also noted by all participants. Multiple decision attributes were interrelated in highly complex ways.
Conclusions: Participants considered numerous attributes in their CHC treatment decisions. A better understanding
of these attributes that influence patient decision-making is crucial in order to inform patient-centered clinical
approaches to care (such as shared decision-making augmented with relevant decision-making aids) that respond
to patients’ needs, preferences, and circumstances.
Keywords: Chronic hepatitis C viral infection (CHC), Anti-viral treatment, Decision attributes, Shared decision-
making aid, Veterans
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Background
Chronic infection with hepatitis C virus (CHC) is a large
public health problem, impacting an estimated three
million people in the United States [1, 2]. Successful
treatment slows disease progression and reduces the risk
of cirrhosis and liver cancer, which often are fatal [3–10].
Historically, antiviral treatment was lengthy and associ-
ated with substantial side effects, with only a modest
chance of success. However, CHC medications are rapidly
changing with the introduction of new direct acting anti-
viral agents which can be combined with older therapies
to reduce use of interferon, or replace interferon therapy
entirely. With these new treatment options, treatment
duration is attenuating for most patients, with associ-
ated side effects becoming less prevalent and less severe
[11–13]. However, the new medications are also sub-
stantially more expensive [14]. In addition, with many
drugs in the development pipeline, future treatments
are anticipated to continue to improve and offer new
and potentially better choices [15].
Providers and patients face a new context for CHC
treatment decision-making. Previously the decision to
treat or delay treatment was framed by tradeoffs among
the severity of side effects, treatment duration, and effi-
cacy [16–18]. Now patients and providers must consider
a rapidly changing set of medication options, a constant
horizon of potentially better medications, and extremely
costly medications [19]. Given these considerations,
watchful waiting may be appropriate for patients with
early stage disease (0/1 stage fibrosis) and significant co-
morbidity. As a result, decision-making around CHC
treatment remains complex and many patients are of-
fered deferral of treatment as an appropriate option.
Patient-centered care postulates that patients’ under-
standing of outcomes expectancies, potential risks and
benefits, and values-informed preferences should guide
treatment decisions, in addition to the clinician’s expert
opinion and evidence [20, 21]. Data suggest that health
outcomes are comparatively better for patients who are
informed about their treatment options, have realistic ex-
pectations of outcomes, participate in setting goals for po-
tential treatments, and are able to link personal values to
their goals [22, 23]. Shared decision-making is a model of
patient-centered care that enables and encourages patients
to play an active role in the management of their own
health [24, 25]. Well-developed, high-quality, formal
decision aids can augment the process of shared decision-
making and enhance patient involvement in the decision-
making process during clinical encounters [26].
Decision-making aids actively involve the patient in
the shared decision-making process and thus, must be
based not only on accurate scientific information, but
also speak to patient perceptions which may influence
the treatment decision. To inform the development of a
relevant CHC treatment decision aid, it is first necessary
to identify specific decision attributes that CHC patients
take into account when faced with a treatment decision.
Previous work that has examined the attributes that influ-
ence patient CHC treatment decisions suggests a complex
array of decision attributes, including both patients’ per-
ceptions of medical attributes related to treatment such as
treatment effects, as well as their perceptions of the im-
pact of treatment on personal life circumstances; little
work has attempted to describe how these decision attri-
butes may be related to each other [17, 27–32].
For exploratory purposes, we used qualitative inter-
views with CHC patients in close proximity to their own
CHC treatment decisions in order to provide a grounded
description of the specific attributes that influence pa-
tients’ decisions around CHC treatment, and relation-
ships between those attributes. For the purposes of this
paper, we define a decision attribute as a patient percep-
tion of treatment, or a broader personal impact of treat-
ment, that influences the treatment decision outcome.
We identified key patient-reported attributes in treatment
decision-making and explored the relationships between
these attributes. We suggest that a grounded understand-
ing of the relationships between decision attributes will be
beneficial in the development of a valid and relevant
decision-making aid for CHC patients.
Methods
Design and sample
We conducted semi-structured qualitative interviews
with CHC patients at four VHA medical centers. Enroll-
ment criteria were patients with a CHC diagnosis seek-
ing care at one of the four VHA medical centers in the
study. Exclusion criteria were 1) patients receiving CHC
treatment at non-VA facilities, and 2) patients who initi-
ated their current course of treatment more than
15 weeks prior to the interview. Patients were not
excluded on the basis of previous treatment for CHC, co-
infection with HIV or hepatitis B, or active or past sub-
stance or alcohol use. In order to compare men’s and
women’s perspectives, we oversampled women to account
for the predominance of males in VHA.
Patients were sampled from each of three stages of the
decision-making process based on medical record notes
entered by their CHC provider. Group 1 was contem-
plating CHC treatment at the time of the interview,
Group 2 had recently declined treatment, and Group 3
had begun treatment within the past 15 weeks. Groups
of patients and potential participants within the groups
were identified by clinicians in CHC clinics and invited
in person and by letter to participate. The groups facili-
tated comparison of decision-making processes among
the groups as well as perceptions of outcomes. From a
clinical standpoint, we expected that the responses from
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the three patient groups would provide complementary
insight into the decision attributes that patients consider
in making treatment decisions as well as perceptions of
outcomes.
Procedures
Interviews were conducted over the telephone. We used
a semi-structured interview guide developed collabora-
tively by the research team (comprised of clinicians in-
cluding a hepatologist, an internist, and a mental health
provider, health services researchers, and social scientists)
early in the project development phase, and based on the
CHC treatment and patient decision-making literatures.
The semi-structured nature of the guide allowed the inter-
viewer to follow relevant topics introduced by the inter-
viewee and open new lines of inquiry when appropriate.
The interviews addressed an array of topics pertaining to
patients’ perceptions of CHC and its treatment, and pa-
tients’ specific considerations when thinking about starting
antiviral treatment.
We first asked patients to share their personal CHC
stories: “How did you find out you had hepatitis C?” and
“What does having hepatitis C mean to you?” and “How
does it affect your everyday life?” Next, we asked specif-
ically about their decision-making process around initi-
ating treatment: “Could you describe your thoughts
about treatment since the time you first found out you
have it?” and “How did you come to think about starting
treatment now?” Next, we asked the primary question
about the most important decision attributes: “What
are/were the most important considerations (or factors)
for you when you think/were thinking about whether or
not to start antiviral treatment?” The interviewer (JZ)
used an iterative respondent debriefing process [33] in
which she repeated back to the interviewee the decision
attributes named, requested confirmation, and invited
additional clarification and elaboration. Patients’ know-
ledge about CHC infection, disease progression, and avail-
able treatments was assessed indirectly through their
responses to interview guide questions.
Written informed consent was obtained from all par-
ticipants for participation in the study. All procedures
were approved by VA Central Institutional Review Board
(HH QUERI RRP: 12–194; Development of a Shared
Decision-Making Aid for Hepatitis C Treatment).
Analysis
All interviews were audio recorded and professionally
transcribed. A summary template was developed based
on the interview guide to capture key points in each do-
main of the interview guide. Four transcripts were inde-
pendently summarized by five team members (JZ, AH, JC,
DS, FK). Summaries were compared in a matrix [34] and
discrepancies resolved by consensus. The remaining tran-
scripts were then summarized by the lead author (JZ).
Transcripts were coded by the lead author in ATLAS.ti
(Scientific Software Development, version 6) and spot-
checked by a second team member. We utilized the con-
stant comparative approach in our analysis [35] consistent
with Grounded Theory [36]. In this approach, discrete
narratives are compared within common themes which
are integrated across narratives in order to articulate a
theory of how the themes are related to each other. The
analytic focus of “decision attributes” was derived a priori
from the interview guide. We coded responses to the pri-
mary question about patients’ most important attributes
and examined the entirety of each interview to identify
additional attributes expressed elsewhere in participants’
accounts.
As coding progressed, coded words and phrases were
compared and grouped into respective themes, and the
codebook and its definitions were revised in an iterative
process. Attribute themes were compiled, tallied, and
ranked by frequency. Results were synthesized by compar-
ing and contrasting coded segments of top decision attri-
bute themes overall, by group, and by gender. Average
number of decision attributes considered was calculated
overall and by group. Percentage frequency of attributes
was calculated and compared by group and by gender.
Using axial coding [37], relationships between the at-
tribute themes were analyzed for co-occurrence (i.e., de-
gree of overlap). Analysis for patterns of co-occurrence
resulted in Glaser’s “theoretical properties of the cat-
egory” which included distinct clusters of co-occurrence.
Examples of these prominent patterns were selected for
visual display in a schematic (“network diagram”) depict-
ing interrelationships of decision attribute themes and
suggesting possible hypotheses for how multiple attri-
butes influence patients’ CHC treatment decisions.
Results
Of the 39 patients recruited, 31 (79.5 %) agreed to par-
ticipate in the study and 29 interviews were completed.
The most common reason for declining to participate
was inability to be reached to complete the consent
process. Interviews lasted 45–60 min on average. The
sample is described in Table 1. Thematic saturation was
reached at 29 participants when no new decision attri-
butes were being reported.
Most frequently reported decision attributes
Across the 29 patients interviewed, we identified a total
of 35 decision attributes that patients considered while
making treatment decisions. At the time of the inter-
views, all CHC treatments offered still involved inter-
feron, though most patients were aware that new drugs
were in development. On average, patients mentioned
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eight (range of 5 to 13) attributes. The decision attri-
butes most frequently reported by patients were: phys-
ical side effects of antiviral treatment (n = 24, 83 %);
treatment efficacy (n = 23, 79 %), new antiviral drugs in
development (n = 16, 55 %); psychological side effects of
antiviral treatment (n = 16, 55 %); and the condition of
the liver (n = 15, 52 %). All patients also identified at
least one attribute related to personal life circumstances,
while the actual attributes named varied according to
patients’ individual situations. The more common attri-
butes which related to patient life circumstances included
family and friend support network, quality of life, and per-
sonal financial pressures. The 24 most frequently reported
decision attributes, which were reported by more than
one patient, are listed in the saturation grid, Table 2.
Physical side effects
Patients expressed general concern that interferon-based
antiviral treatment can cause severe side effects. The
most common specific physical side effects mentioned
were fatigue, flu-like symptoms, and nausea. Many also
expressed concern around doctors’ inability to predict
the severity of side effects that they might experience, if
they chose to undergo treatment. There was variation in
how physical side effects influenced patients’ decisions.
They were an impetus behind delaying or declining
treatment for some patients (e.g., “If there were some
side effects to it, I’d rather not take it”), while others
imagined the side effects would be manageable (e.g.,
“I’m still a little bit leery about the nausea and stuff but
I really believe it’s manageable”), and still others saw
them simply as an unavoidable aspect of needed treat-
ment (e.g., “[The side effects are] worth it if you get rid
of something. It’s like going in for chemotherapy because
if it kills off the cancer, who cares? You put up with the
bad to get the good”).
Treatment efficacy
Patients referred to treatment efficacy by expressing
hope that the treatment would have the desired benefit
of curing the illness or getting rid of the virus from the
body and restoring health: “I weighed whether I want to
have hepatitis in me or at least try to get it out of my
system. So to live a longer life, I decided that it was
worth going through the treatment to try to change the
course of the virus.” Some patients were aware that the
existing treatments had a particular cure rate and
expressed concern that the treatment may or may not be
effective in their particular case: “I’m not going to take
that kind of debilitating side effect for a 40 % cure rate.
Table 1 Description of the sample (n = 29)
n(%)
Group
Group 1 12 (41)
Group 2 9 (31)
Group 3 8 (28)
Cirrhosis
Group 1 6 (21)
Group 2 2 (7)




Under 45 2 (7)
45–55 6 (21)
56–65 21 (72)
Time since CHC diagnosis
<1 year 4 (14)
1–5 years 15 (52)
6–10 years 8 (28)
>10 years 2 (7)
Table 2 Saturation grid: Decision attributes considered in CHC
treatment decisions (n = 29)
Decision Attribute n %
Physical side effects 24 83 %
Efficacy/Cure rate 23 79 %
New drugs in development 16 55 %
Psychological/Mental health side effects 16 55 %
Condition of liver 15 52 %
Treatment regimen 12 41 %
Support network/family help 12 41 %
Other illnesses 12 41 %
Quality of life 11 38 %
Length of treatment 9 31 %
Financial pressures/being able to work 7 24 %
Age/life span 7 24 %
Doctor’s recommendation 7 24 %
Medical privacy/stigma 7 24 %
Fear of transmitting illness 6 21 %
Urgency to treat 6 21 %
Trust in provider 5 17 %
Travel to VHA 5 17 %
Location/stability of living situation 5 17 %
Caregiver responsibilities 4 14 %
Quitting drinking/drugs 4 14 %
Not wanting biopsy 3 10 %
Other people’s experiences with treatment 3 10 %
Using alternate/natural treatment/herbs 3 10 %
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I’m not going to quit drinking for a 40 % cure rate. I’m
not going to feel that sick for a 40 % cure rate.”
New treatment drugs in development
Patients expressed awareness that new medications were
currently in development and would become available
soon. This anticipation influenced decision-making be-
cause of their belief that the new treatment would be
preferable to existing treatment. Most patients were op-
timistic about the promise of new medications, with
many expressing that they would delay treatment in the
hopes of “something better”: “Maybe something better
will come down because that’s what everybody keeps
telling me; every time I talk to the doctors, there’s some-
thing coming down the pike. We’ll be getting some new
treatments come along and they won’t quite be so bad.”
Similarly, another patient said, “I can’t remember what
[my doctor] said the side effects and everything else was
of the [current] treatment, but it didn’t sound like fun so
I figured I’d wait for an easier treatment.” In contrast, a
few patients felt that the wait would be too long when
reasonable treatment was available now: “[My doctor]
explained to me that they have a new treatment that it
was in trials and it seemed promising for treatment of
hepatitis C. She had said it seemed to look positive be-
cause the patients that were undergoing that seemed to
be able to handle that treatment. But I was willing to
undergo the treatment they have going now because I
feel that I’m strong enough to undergo it.”
Psychological side effects
Patients expressed concern about the possible mental
health side effects of interferon-based treatment as a
consideration in their decision-making. They noted con-
cerns about depression, anxiety, changes in moods, feel-
ing irritable, worsening of post-traumatic stress disorder
(PTSD) symptoms, or suicidal thinking. For example,
one patient said, “The treatment that they’re offering
now actually has a side effect that leaves you psycho-
logically drained and mood swings and things like that.
And so I was concerned that if I did that now with me
being in school and employed, how would that affect
me.” Some patients who had controlled depression or a
history of depression worried about it becoming an issue
again and this was a deterrent to treatment: “The treat-
ments that are available now, they cause depression or
whatever. And I’ve been kind of holding off on dealing
with that because I’m already depressive and I didn’t
want to exacerbate that. So that’s the main reason that I
haven’t gone on with the treatment.” Other patients con-
sidered this attribute, but ultimately decided they were
not concerned about mental health side effects impact-
ing them if they chose treatment: “[Depression] was one
of the [concerns], ‘cause I’ve never had depression. So, I
didn’t know how to act on that. It said suicidal thoughts
when I was reading the paperwork. I said, I don’t think
I’m that bad off. I don’t think I’ll ever get that away. So,
I decided to go on and try [treatment].”
Condition of the liver
Patients expressed concern about the health status of
their liver including the stage of their liver disease, the
presence or absence of cirrhosis, or other biomarkers
such as viral count or liver enzymes. They tended to de-
scribe their liver health in general terms such as “bad/
high/damaged” or “not so bad.” “Bad” liver health was
seen as reason to treat the illness soon: “Well now that I
know I’m at stage three, it’s a big concern on the liver.
You know you only get one [liver], we’re just gonna try
to get it fixed through what’s available for me right
now.” “Not so bad” liver health was seen as a reason for
possibly delaying treatment: “[My doctor] pretty much
said that my enzymes are just I think one above the top
[of the normal] range, so nothing’s really bad yet. I don’t
know, so I haven’t really thought about treatment or
whatever either. And she said I wouldn’t have to worry
about it for a while basically.” Some patients were add-
itionally concerned with the unpredictability of the pro-
gression of liver damage, and the potential irreversibility
of reaching worse stages of liver health: “I just don’t
know when it’s going to flip from stage three to stage
four and that’s kind of worrisome. You know I was told
stage four there’s no turning back; you know your liver’s
gone when it goes to cirrhosis.”
Analysis by patient group
We analyzed the frequency of decision attributes broken
down by patient group. The number of attributes con-
sidered was similar across the groups. Group 1 patients
(contemplating) on average reported slightly more attri-
butes than Group 3 patients (recently started treatment),
while Group 2 patients (recently declined treatment) re-
ported the fewest attributes (8.75, 8.25, 7.75 attributes,
respectively). All groups showed similar overall patterns
with respect to the relative frequencies of the decision
attributes they mentioned. However, Group 1 and 3 pa-
tients were more likely to identify treatment efficacy
(92 % and 88 %) than Group 2 patients (56 %). Addition-
ally, physical side effects were identified more frequently
by Group 1 patients (92 %) than by Group 2 or 3 pa-
tients (78 % and 75 %). Fifty percent of Group 3 patients
endorsed two decision attributesa (difficulty of frequent
travel to VHA and urgency to treat) that did not appear
in top attributes of the other two groups (Table 3).
Analysis by patient gender
We analyzed the frequency of decision attributes identi-
fied by male (n = 21) and female (n = 8) patients. Both
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male and female patients named physical side effects
(88 % of women and 81 % of men) and treatment effi-
cacy (88 % of women and 76 % of men) as important at-
tributes in their decisions. However, female patients more
frequently than males noted the impact of experiencing
medical privacy and stigma concerns (50 % of women and
14 % of men) as decision attributes. Patients were con-
cerned about maintaining privacy around their illness sta-
tus among family members, coworkers, and community
members, and the impact of social stigma associated with
a communicable disease, either threatened or actually ex-
perienced. Female patients (25 %) also noted the impact
of stress on primary partner relationships, and not hav-
ing to pay for treatment in VHA, whereas none of the
male patients mentioned these decision attributes.
Thus, while women and men considered the same top
decision attributes in their CHC treatment decision-
making processes, social attributes such as stigma/privacy
concerns and impact on primary partner relationships, as
well as not having to pay for treatment in VHA, were
more common among women.
Relationships between decision attributes
Decision attributes were related to one another in
highly complex ways within patient descriptions of
their decision-making processes. Certain attributes fre-
quently co-occurred, forming patterns in how patients
tended to consider various attributes to conjunction
with other attributes. Co-occurrence patterns were
consistent across patient groups. Figure 1 illustrates
selected relationships amongst decision attributes.







1 Efficacy/cure rate (92 %) Physical side effects (78 %) Efficacy/Cure rate (88 %)
2 Physical side effects (92 %) Psych/Mental side effects (67 %) Physical side effects (75 %)
3 New drug coming out (67 %) Treatment regimen (67 %) Other illnesses (63 %)
4 Quality of life (67 %) Efficacy/cure rate (56 %) Travel to VHA (50 %)
5 Psych/Mental side effects (58 %) New drug coming out (56 %) Urgency to treat (50 %)
6 Condition of liver (58 %) Condition of liver (56 %)
Fig. 1 Selected Relationships Between Decision Attributes
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Physical side effects cluster
Physical side effects were closely related to a cluster of
other decision attributes. The most common association
was with family and friend support networks. Patients
expressed concerns that the severity of physical side ef-
fects was unknown and it was difficult to predict if the
side effects would prevent them from going about their
usual routines. As a result, the availability of family and
friend support networks becomes a related attribute of
concern, should they require help. Closely related to this
was the attribute of family financial obligations. For ex-
ample, some patients were concerned that physical side
effects may prevent them from working and paying bills:
“I was wondering, am I going to be able to continue
working [due to side effects while on treatment]? What’s
it going to do with our finances? I mean there was just a
lot of ‘what ifs’. What am I going to do?” This patient
also noted concerns about efficacy of treatment, side ef-
fects, and finances: “Four years ago I said no [to treat-
ment]. There is no way because doing the treatment
was such a long process. Didn’t know how I was going
to respond to the treatment. I did a lot of research on it
and it didn’t sound like it was as effective as what I
would think it should be. And plus the side effects, and
I was worried about our finances of whether that I
would be ill and not be able to go to work.” Some pa-
tients were concerned about the impact of side effects
in light of the stability of their living situation, or on
their ability to care for their families: “[My doctor] was
unwilling to start me [on treatment] right now, because
of the side effects. Plus my wife is disabled and I’m
pretty much here with her. If something happened to
me then there’s nobody here to take care of me.”
New drugs becoming available cluster
The promise of the on-going development of new CHC
medications was also an attribute that frequently dem-
onstrated co-occurrence with other decision attributes.
When considering new treatments on the horizon, pa-
tients considered this attribute in conjunction with a
constellation of other decision attributes including:
characteristics of existing treatment, treatment regime,
length of treatment, chances of treatment success, doc-
tor’s recommendation, support networks, physical side
effects, mental health side effects, liver status, progres-
sion of illness, social support, as well as a general sense
of urgency or lack of urgency to address the issue of the
illness in the patient’s life. For example, one patient ex-
plained, “I’m still not sure if I don’t want to take it or
not. [My doctor] told me it’s better for me not to really
take it at the stage I’m in right now. So if it’s come to a
point where…I have to take it, yeah, I’m going to take it.
But as of right now, he told me don’t. At the stage I’m
in, don’t worry about it right now— they’re working on
two different types [of new treatment] right now. I think
the second one they’re coming up with, it don’t have no
side effects at all or little side effects. So that’s the one
he may introduce me to in the future.” Another patient
noted the role of support in deciding to proceed with
currently available treatment: “[My doctor] said there
were some [future treatments] that would not have as
severe side effects but I just went ahead and went on
with the Pegasys. It’d be real nice if you can get cured
and no drastic side effects. [But] I had the support to go
ahead and do it [the currently available treatment] and
it’s just a peace of mind for me. That it’s getting taken of
care of; I’m not sitting here harboring something that
could just get worse.”
Discussion
Patients weigh a number of decision attributes when
considering CHC treatment options. The decision attri-
butes most frequently reported by patients were: phys-
ical side effects of antiviral treatment, treatment efficacy,
new antiviral drugs in development, psychological side
effects of antiviral treatment, and the condition of the
liver. The number of attributes considered and the most
frequently reported attributes varied somewhat based on
the patient group (contemplating treatment, recently de-
clined treatment, or recently begun treatment). Decision
attributes were interrelated in patients’ decision-making
narratives and this was consistent across groups. Rela-
tionships between decision attributes included: physical
side effects and their unpredictable severity were fre-
quently considered in conjunction with support net-
works and financial obligations, and the promise of new
treatment drugs was considered in conjunction with a
number of other attributes.
The overall patterns of most frequently mentioned de-
cision attributes were similar across the three patient
groups, with a few notable differences. The patients who
were actively contemplating treatment considered
slightly more decision attributes and were more likely to
identify physical side effects than the other patient
groups. These undecided patients may have been actively
seeking as much information as possible to guide their
decision-making. Patients who had recently started
interferon-based treatment may have been motivated by
an urgency to treat despite the promise of new drugs be-
coming available; these patients also noted the challenge
of travel to VHA due to the frequent trips they made to
receive treatment.
Our analysis by gender suggests that men and women
typically consider the same decision attributes, but
women may be more likely than men to consider certain
social attributes (such as stigma and primary partner re-
lationships) and financial attributes (such as the cost of
treatment). Further study and larger sample sizes are
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needed to better understand the potential role of gendered
decision attributes in patient decision-making around
CHC treatment. These findings by groups and gender
bring to light two important but often overlooked sets of
decision attributes related to decision-making [38]. The
first are logistical attributes (like travel and cost) that may
moderate the relationship between behavioral intention
and action. The second are affective states of urgency, or
lack of urgency, that impact patients’ perceptions of time-
liness, the desire to make and act on a decision within a
certain timeframe, and peace of mind.
The most frequent decision attributes identified across
the groups and between genders primarily reflected pa-
tients’ perceptions of medical states (liver health) and pre-
dictions of impact of treatment. However, other common
attributes were tied to patients’ specific life circumstances
and preferences. Patterns in the co-occurrence of decision
attributes highlight the ways in which “medical” attributes
and “life circumstance” attributes were closely woven to-
gether in patient experiences. Thus while patients’ treat-
ment decisions were influenced by their personalized
medical risks associated with their illness status, they were
also influenced by the ways in which these risks interfaced
with their unique life circumstances.
The need to consider personalized medical risk in con-
junction with personal life circumstances and prefer-
ences [39], and the need to foster mutual engagement in
care that is likely conducive to subsequent adherence
and completion of complex treatment regimens [40, 41]
makes shared clinical decision-making particularly ger-
mane to CHC treatment decisions. These results shed
light on decision attributes that influence patient CHC
treatment decisions and reveal complex relationships be-
tween medical attributes and life circumstance attributes
in these decisions. They help illuminate common percep-
tions patients bring to the table in a shared decision-
making context, and can be used to help inform a relevant
decision-making aid.
Shared decision-making requires values clarification
by patients involved in the decision-making process;
quality standards exist for validation of decision aids,
and these standards typically include a standardized
process for values clarification [26, 42, 43]. Patients
would likely benefit from a tool to help identify rele-
vant decision attributes and their relationships, and
clarify relative importance/impact on overall circum-
stances in order to make a decision that is not only
consistent with their values, but also consistent with
their personalized risk association with CHC [42].
Such a tool will need to take into account the attri-
butes and relationships between attributes discussed
here. In addition, findings by patient group and gender
can help tailor versions of a decision-making aid for
particular patient sub-groups.
While some qualitative studies have examined non-
Veteran patient attitudes towards CHC treatment in
general [17, 27–29] and others have examined treatment
decision-making among individuals co-infected with
HIV and CHC [30–32], to the best of our knowledge,
this is the first qualitative study of Veterans’ rationales
and thought processes regarding the initiation of CHC
treatment. Although most of the top decision attributes
endorsed by patients may not remain very relevant with
the new interferon-sparing treatments, many attributes
will still be important – such as condition of liver, other
illnesses, life span, and the promise of newer drugs in
development. Thus our work and the resulting tool will
continue to have implications for antiviral treatment-
related shared decision-making and can be modified or
refined as new treatments become available.
These findings should be considered in light of several
limitations. Our study was limited to four sites only.
However, the sites represented small and large facilities
and geographic diversity. The VHA serves primarily
men; to account for this we purposely oversampled
women for the study. This study was carried out entirely
within the VHA healthcare system and as such, the find-
ings may be particular to VHA users with CHC. Com-
pared to non-Veteran populations, Veterans receiving
care through VHA have a greater likelihood of psychi-
atric comorbidities and substance use, are more likely to
end treatment early, and tend to respond to treatment at
lower rates [44]. Finally, our qualitative methods are un-
able to determine the nature or strength of the associa-
tions among the decision attributes that we identify;
future studies should examine this issue.
As the treatment landscape for CHC rapidly continues
to change, more studies are required to understand the
multidimensional and interrelated attributes that pa-
tients consider in their treatment decisions. The widen-
ing availability of new drugs with fewer side effects calls
for additional studies to update our knowledge of how
patients respond to new and different treatment choices.
Because of the prevalence of individual life circumstance-
related attributes, future work in this area should include
a broad diversity of patients to increase our understanding
of how distinctions such as race, socioeconomic class,
education, substance use histories, and incarceration influ-
ence lived context for CHC decision-making. Due to the
intensive nature in which patients undergoing CHC treat-
ment interact with their healthcare system, further study
is also warranted with Veterans who use other healthcare
systems, as well as non-Veterans.
Conclusions
Patients and providers face complex CHC treatment de-
cisions within a dynamic context of changing options.
Patients consider multiple decision attributes related to
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personalized medical risk as well as life circumstance, and
these attributes are interrelated in complex ways. In the
face of rapidly changing treatment options as new drugs
become available, understanding the role of decision attri-
butes that patients bring to the decision-making process is
crucial. The prevalence of CHC in the general population,
combined with the constantly evolving array of treatment
options, make CHC decision-making a persistent issue with
changing options for years to come both within and outside
the VHA. As new treatments become available, these find-
ings can guide clinicians to provide patient-centered deci-
sional support to address key attributes that influence
patients, and contribute to shared decision-making aids.
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